Q-omics provides the consensus-scored ADM profile across patient tissues and cancer cell-line models. ADM expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ADM is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ADM RNA expression shows 19,778 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where ADM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADM survival associations across molecular data types. ADM RNA expression shows survival associations in the most cancer types (27), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADM RNA expression–survival associations across cancer types. High ADM expression shows unfavorable associations in HNSC, LUAD, KICH, UCS, ACC and MESO. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ADM RNA expression.
This table summarizes ADM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ADM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADM shows lower tumor expression in BRCA and higher tumor expression in KIRC, HNSC, THCA, UCEC and LUSC. The KIRC box plot shows higher ADM RNA expression in tumor versus normal tissue (log2 FC = +2.861, t-test p < 0.001).
This table shows molecular features associated with ADM in patient tissues and cancer cell lines. In patient samples, ADM shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
